KR20200123434A - Allo-HCT 시술받은 환자에서 혈액암을 치료하는데 사용하기 위한 GM-CSF 또는 GM-CSF-수용체에 대한 리간드 - Google Patents

Allo-HCT 시술받은 환자에서 혈액암을 치료하는데 사용하기 위한 GM-CSF 또는 GM-CSF-수용체에 대한 리간드 Download PDF

Info

Publication number
KR20200123434A
KR20200123434A KR1020207025898A KR20207025898A KR20200123434A KR 20200123434 A KR20200123434 A KR 20200123434A KR 1020207025898 A KR1020207025898 A KR 1020207025898A KR 20207025898 A KR20207025898 A KR 20207025898A KR 20200123434 A KR20200123434 A KR 20200123434A
Authority
KR
South Korea
Prior art keywords
csf
ligand
cells
hct
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207025898A
Other languages
English (en)
Korean (ko)
Inventor
소니아 투게스
부르크하르트 베허
Original Assignee
유니베르시태트 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by 유니베르시태트 취리히 filed Critical 유니베르시태트 취리히
Publication of KR20200123434A publication Critical patent/KR20200123434A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207025898A 2018-02-22 2019-02-22 Allo-HCT 시술받은 환자에서 혈액암을 치료하는데 사용하기 위한 GM-CSF 또는 GM-CSF-수용체에 대한 리간드 Ceased KR20200123434A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (1)

Publication Number Publication Date
KR20200123434A true KR20200123434A (ko) 2020-10-29

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025898A Ceased KR20200123434A (ko) 2018-02-22 2019-02-22 Allo-HCT 시술받은 환자에서 혈액암을 치료하는데 사용하기 위한 GM-CSF 또는 GM-CSF-수용체에 대한 리간드

Country Status (11)

Country Link
US (3) US11655293B2 (https=)
EP (1) EP3755715A1 (https=)
JP (1) JP7278296B2 (https=)
KR (1) KR20200123434A (https=)
CN (1) CN111886248B (https=)
AU (1) AU2019224550A1 (https=)
BR (1) BR112020017253A2 (https=)
CA (1) CA3091536A1 (https=)
MA (1) MA51893A (https=)
MX (2) MX2020008792A (https=)
WO (1) WO2019162472A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367688A (zh) 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
MA37946B1 (fr) 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Also Published As

Publication number Publication date
JP7278296B2 (ja) 2023-05-19
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
RU2020129401A3 (https=) 2022-03-22
US20190256587A1 (en) 2019-08-22
MA51893A (fr) 2020-12-30
CN111886248B (zh) 2025-03-04
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
AU2019224550A1 (en) 2020-09-17
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
US12384839B2 (en) Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
KR20220068240A (ko) 암 치료를 위한 암 요법과 사이토카인 조절 요법의 조합
TW202043276A (zh) 肝毒性之治療
US20220241333A1 (en) Modulation of t cell cytotoxicity and related therapy
JP2025508129A (ja) Ｅｐｏ受容体アゴニストおよびアンタゴニスト
JP7148151B2 (ja) 抗レナラーゼ抗体および抗ｐｄ－１抗体を用いる、がんを処置するための組成物および方法
US20240226168A1 (en) Engineered nk cells and uses thereof
US20230210984A1 (en) Adoptive immunotherapy
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
US20240115678A1 (en) Personalized multidisciplinary cancer therapy
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
EP3623382A1 (en) Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2024014523A1 (en) Anti-aqp3 antibody cancer therapy
Field Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Reighard A natural killer cell-centric approach toward new therapeutics for autoimmune disease
Alizadeh Doxorubicin and T helper lymphocytes: Unexpected allies against cancer
Miller Interferon regulatory factor 1 (IRF-1) directs IL-4/IL-13 induced death of neonatal Th1 cells
Cabrera-Pérez Examining helper T-cell recovery after sepsis
Nesbeth Endogenous antitumor immunity elicited by adoptively transferred lymphocytes through CCL5 and CD40L signaling, and dendritic cell depletion
Cao et al. REGULATORY IMMUNE CELLS IN KIDNEY DISEASE

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200908

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220221

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240930

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241211

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D